Skip to content

Clinical application of 3D contrast enhanced ultrasound and virtual navigation imaging methods in prospective precision evaluation the effect of minimal invasive ablation or TACE treatment of HCC

Clinical application of 3D contrast enhanced ultrasound and virtual navigation imaging methods in prospective precision evaluation the effect of minimal invasive ablation or TACE treatment of HCC

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023888
Enrollment
Unknown
Registered
2019-06-15
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

control group:Conventional ultrasound assessment
experimental group :3D navigation CEUS assessment

Sponsors

Fudan University Zhongshan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnized as HCC by histopathological results or other imagings; 2. The number of lesions in the liver less than three and the maximum size of the lesions less than 3cm; 3. Patients who will undertake radiofrequency ablation, microwave ablation or TACE; 4. Patients with integrated ducuments who accept follow-up using US\MRI\CT; 5. Patients aged 18 to 80 years old without ultrasound contrast agent allergy and severe cardiovascular or respiratory system diseases; 6. Patients with clear cnsciousness understand and sign for the written informed consent, and patients can coordinate with doctors to finish the multiple ultrasound examinations including conventional contrast-enhanced ultrasound,CEUS-MRI fusing navigation,3D contrast-enhanced ultrasound.

Exclusion criteria

Exclusion criteria: 1. Patients who Lack of reliable clinical diagnosis documents; 2. Pregant patients; 3. Patients with sever cardiovascular or respiratory diseases; 4. Patients who are allergic to ultrasound contrast agent.

Design outcomes

Primary

MeasureTime frame
blood perfusion;

Countries

China

Contacts

Public ContactWang Wenping

Fudan University Zhongshan Hospital

puguang61@163.com+86 13681975670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026